PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.25
D/E ratio exceeding 1.5x Healthcare median of 0.06. Howard Marks would check for debt covenant compliance and refinancing risks.
1.73
Concerning net debt at 1.25-1.5x Healthcare median of 1.26. Martin Whitman would look for hidden assets or restructuring potential.
No Data
No Data available this quarter, please select a different quarter.
1.89
Current ratio 50-75% of Healthcare median of 2.69. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.